GMP Neoantigen

GMP Neoantigen | Clinical Grade Neoantigen Peptide Synthesis | Personalized Cancer Vaccine Ingredients | Science-Peptide

Need GMP Neoantigen for clinical trial or IND filing? Science-Peptide provides cGMP compliant Neoantigen peptide synthesis, supporting long peptides, refractory sequences, multiple modifications, strict endotoxin control, and complete documentation to help personalized tumor immunotherapy. Welcome to contact us.

As your new antigen research moves from laboratory validation to clinical trials, the quality standards for peptide raw materials must be upgraded. gMP Neoantigen is no longer "just enough", but must meet the stringent requirements of Good Manufacturing Practice (cGMP) - from material traceability to process control and environmental monitoring to documentation, every detail must be able to withstand regulatory scrutiny. -Science-Peptide has been in the peptide business for more than 20 years, and has an independent cGMP manufacturing facility that can provide you with GMP Neoantigen services from toxicology, clinical to commercial batches. We understand the importance of personalized neoantigen projects. We understand the special characteristics of personalized neoantigen projects: variable sequences, tight schedules, and flexible batch sizes. For this reason, we have established a cGMP production system specifically adapted to the characteristics of Neoantigen, to ensure compliance, and to respond quickly to your individual needs.

GMP Neoantigen refers to neoantigenic peptides produced in accordance with the current Good Manufacturing Practice (cGMP) for human clinical trials (e.g., personalized cancer vaccines, T-cell therapies, etc.) or as APIs for IND filings. Compared with research-grade peptides, GMP Neoantigen has strict differences in the following aspects:

• Production environment: done in a clean area (ISO class 7/8) to avoid microbial and particulate contamination.
• Material control: All raw materials (amino acids, resins, solvents) are tested and qualified, and suppliers are audited.
• Process control: Critical Process Parameters (CPP) are controlled and each step is documented.
• Quality testing: In addition to conventional purity and molecular weight, mandatory testing for endotoxin, microbial limit, residual solvents, etc.
• Documentation system: Provide complete batch production records, deviation handling, validation documents, support IND declaration.

Depending on the stage of application, GMP Neoantigen can be categorized as:

• Toxicology Lot: Used for GLP toxicology studies, must meet GLP/cGMP cross requirements.
• Clinical Lot: For Phase I/II/III clinical trials, strictly in accordance with cGMP.
• Process validation lot: for process performance qualification (PPQ) to support commercial production.

1. cGMP facilities that meet international standards
Our independent GMP Neoantigen manufacturing facility is located on 10 acres of land and was designed and built in strict compliance with the cGMP requirements of the US FDA, European EMA and Chinese NMPA. Key facilities include:

• Separate air-conditioning and purification system (HVAC), clean area up to ISO class 7/8.
• Automated solid-phase synthesis workshop with linear scale-up.
• Preparative HPLC purification system, suitable for different scales.
• Freeze-drying workshop with many industrial freeze-dryers.
• Complete QC lab: HPLC, UPLC, LC-MS, GC, endotoxin detector, etc.

All equipment is validated to ensure the reliability and reproducibility of the GMP Neoantigen manufacturing environment.

2. Process development capabilities for the characterization of new antigens
Neoantigen peptides are often characterized by long sequences, high hydrophobicity and difficult synthesis. We have combined our 20 years of peptide synthesis experience with cGMP requirements to develop a robust process for GMP Neoantigen:

• Long peptide synthesis: use fragment condensation or microwave-assisted synthesis to improve the yield of crude peptide.
• Purification of insoluble peptides: special solvent systems are developed to ensure product solubility and purity.
• Process scale-up: Simulate the scale-up in the pilot plant, identify and solve the scale-up effect in advance.
• Impurity profiling: comprehensive identification of process impurities and degradation products in accordance with ICH Q3.

3. Rigorous quality control
Each batch of GMP Neoantigen is subjected to release testing and stability checks:

• Release testing: Appearance, content (amino acid analysis), purity (HPLC), related substances, residual solvents (GC), elemental impurities (ICP-MS), moisture, bacterial endotoxins, microbiological limits (aerobic bacteria, molds, yeasts).
• Method validation: All analytical methods were validated in accordance with ICH Q2.
• Stability studies: Long-term, accelerated and impact factor tests in accordance with ICH Q1 to support the development of review periods.
• Controls:Provide working controls and official control calibrations.

4. Complete documentation and registration support
We understand the GMP Neoantigen filing requirements and can provide:

• Process development report (including the process of determining key process parameters).
• Process validation program and report (with validation batch data).
• Analytical Method Validation Report.
• Stability study data (long-term, accelerated, impact factors).
• Heterogeneous mass spectrometry report (with structural corroboration).
• Batch production records (complete and traceable).
• Change control and deviation handling records.
• Cooperate with clients to undergo on-site audits by domestic and foreign drug regulatory agencies.

5. Flexible and rapid personalized services
New antigen projects are often "one person, one solution", with special requirements for production scale and lead times:

• Flexible batch sizes: from a few hundred milligrams (for a small number of patients) to a hundred grams (for clinical trials), we can handle it all.
• Fast Response: For GMP Neoantigen to set up a green channel, the routine cycle is 30% shorter than the general cGMP project.
• Multi-Project Parallelism: With multiple independent production lines, we can handle peptide production for multiple patient samples at the same time.
• Confidentiality: The new antigen sequence is the core asset of our clients, and we have signed a strict confidentiality agreement to ensure the security of the data system.

1. Individualized New Antigen Vaccine (IIT/IND)
GMP Neoantigen, which is used in investigator-initiated clinical trials (IIT) or registered clinical trials, is usually administered as a peptide mixture. We can provide high purity, low endotoxin peptides that meet the requirements for clinical use, and we can assist in the preparation of regulatory submissions.

2. T-cell therapy products
GMP Neoantigen is used to stimulate, screen or expand neoantigen-specific T cells for use in over-the-counter T cell therapy (ACT). We provide biotin-labeled GMP Neoantigen to facilitate the preparation of MHC tetramers for sorting.

3. Neoantigen-specific TCR-T development
GMP Neoantigen is required for TCR affinity testing, functional validation or as a positive control in TCR-T cell therapy. We can provide sufficient and stable peptide to support the whole process.

4. Diagnostic kit quality control products
As a quality control product for companion diagnostic reagents, GMP Neoantigen requires a high degree of lot-to-lot consistency. We provide multi-batch stability data to support kit registration.

1. Needs communication and sequence assessment
You provide us with the new antigen sequence (mutation site must be specified), required scale, purity requirements and intended use. We evaluate the difficulty of synthesis, process feasibility, and develop a preliminary project plan.

2. Process development and scale-up
Process development was carried out under non-GMP conditions to determine the optimal synthesis and purification conditions. After the completion of small-scale trials, scale-up simulations were carried out in a cGMP pilot plant to confirm the robustness of the process.

3. GMP production

• Material Preparation: All raw materials are qualified by QC inspection and released.
• Synthesis: Solid-phase synthesis in a clean area with real-time monitoring of key process parameters.
• Purification: Preparative HPLC was used to purify to the target purity, and the target fractions were collected.
• Freeze-drying: Freeze-dried in a clean area to ensure low moisture and good appearance.
• Packing: Packed under sterile conditions, labeled and sealed.

4. Quality control
Each batch of product is subjected to a full set of release tests, including physical and chemical indicators and microbiological indicators. Stability studies are also carried out.

5. Delivery of documents
Provide complete batch production records, inspection reports (COA), process validation reports, stability data, etc., and support customer declarations.

6. Shipment
Cold chain transportation (if required) to ensure product stability during transportation.

1. 20 years of peptide experience, specializing in difficult problems
We have been specializing in peptides for more than 20 years, and we have a deep understanding of the technical difficulties in GMP Neoantigen synthesis (e.g., long peptides, refractory peptides, multi-site mutations) and mature solutions. We can always find a solution for the difficult peptides brought by our customers.

2. Compliant facilities, which can withstand audits
Our cGMP production base strictly meets the requirements of FDA, EMA, NMPA, and has successfully cooperated with many customers to pass the on-site audits of domestic and foreign pharmaceutical regulatory agencies. Our documentation system is complete and ready for inspection.

3. Personalized service, matching new antigenic rhythms
New antigen programs are often time-critical, small batch and highly variable. We have established a flexible cGMP manufacturing system that allows us to respond quickly while ensuring compliance. Multiple patient-derived GMP Neoantigen programs are manufactured in parallel without interference.

4. Complete declaration support
We provide not only peptides, but also a complete set of data and documents to support IND filing. From process development reports to stability data, we can help customers save a lot of time.

5. Confidentiality and IP protection
The new antigen sequence is a core asset. We have signed a confidentiality agreement to keep the project information strictly isolated and the data system secure. We have been working together for many years without any leakage.

A cell therapy company (China): To develop a personalized neoantigen vaccine, we needed to synthesize 30 GMP Neoantigen (long peptide 25-35aa) for 10 patients. We delivered all peptides within 3 weeks using a fragmentation strategy. The client used these peptides to prepare a vaccine that successfully entered the IIT study, and an immune response has been observed in the first patients.

Whether you are in the IIT phase or preparing for IND filing, Science-Peptide can provide you with GMP Neoantigen manufacturing services that are compliant, efficient and reliable. Our technical and quality management teams look forward to working with you to advance the development of personalized tumor immunotherapy.